Yes it may be good for Long-term holders since it would enable PIP to argue for perpetual stream of payments associated with commercial value of ST-246 as opposed to finite (10-year term) that Parsons originally set. However, all was not good from summary I read in Americanlawyer article posted 6 days ago under title "Parsons Allows PharmAthene to Introduce Vaccine Profit Data on Remand". End of first paragraph notes this may set final decision back to the end of the year. This would explain recent stock drop as shorter term investors pull back on delay despite otherwise positive decision from long term perspective.
This link provides great news. SIGA stockholders own indirectly more assets then they think.
Evidently Perelman has been hiding information about SIGA's profitable ownership of a smallpox vacince. Not only that but there is a marketing partnership with PIP and the legal dispute is over profits only from this vaccine.
The link in this thread leads to a story with the following headline and first sentence:
Parsons Allows PharmAthene to Introduce Vaccine Profit Data on Remand
PharmAthene Inc. can reopen the record to add new financial data in its long-running dispute with Siga Technologies Inc. over the profits of a smallpox vaccine the two companies had partnered to market, the Delaware Court of Chancery ruled today.
An alternative explaination for this reported information could be that Parsons is confused about the facts.
Ah good, it posted. You can find the story at the Delaware Business Court Insider.
Maybe this will post: